BR9913323A - Processo para vacinar um mamìfero contra umestado doentio, composição de vacina, uso de umcomposto, e, combinação de componentes paraadministração separada, sequencial ouconcomitante no processo - Google Patents

Processo para vacinar um mamìfero contra umestado doentio, composição de vacina, uso de umcomposto, e, combinação de componentes paraadministração separada, sequencial ouconcomitante no processo

Info

Publication number
BR9913323A
BR9913323A BR9913323-7A BR9913323A BR9913323A BR 9913323 A BR9913323 A BR 9913323A BR 9913323 A BR9913323 A BR 9913323A BR 9913323 A BR9913323 A BR 9913323A
Authority
BR
Brazil
Prior art keywords
compound
vaccinating
sequential
separate
combination
Prior art date
Application number
BR9913323-7A
Other languages
English (en)
Inventor
Jehad Charo
Rolf Kiessling
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BR9913323A publication Critical patent/BR9913323A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

"PROCESSO PARA VACINAR UM MAMìFERO CONTRA UMESTADO DOENTIO, COMPOSIçãO DE VACINA, USO DE UMCOMPOSTO, E, COMBINAçãO DE COMPONENTES PARAADMINISTRAçãO SEPARADA, SEQUENCIAL OUCONCOMITANTE NO PROCESSO". Um processo de vacinaçãode um mamífero contra um estado doentio, compreendendo aadministração ao referido mamífero, em um vetor apropriado, deuma seq³ência de nucleotídeo codificando um peptídeoantigênico associado com o estado doentio, adicionalmenteadministrar ao referido mamífero um composto que melhora asrespostas imunes tanto humoral como celular iniciadas pelopeptídeo antigênico, o composto sendo selecionado dentre a listaaqui contida, em que o composto é preferivelmente Tucaresol ouum sal fisiologicamente aceitável ou éster do mesmo, ondeapropriado.
BR9913323-7A 1998-08-26 1999-08-25 Processo para vacinar um mamìfero contra umestado doentio, composição de vacina, uso de umcomposto, e, combinação de componentes paraadministração separada, sequencial ouconcomitante no processo BR9913323A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9818627.3A GB9818627D0 (en) 1998-08-26 1998-08-26 Improvements in dva vaccination
PCT/EP1999/006217 WO2000012121A1 (en) 1998-08-26 1999-08-25 Method of dna vaccination

Publications (1)

Publication Number Publication Date
BR9913323A true BR9913323A (pt) 2001-12-04

Family

ID=10837881

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9913323-7A BR9913323A (pt) 1998-08-26 1999-08-25 Processo para vacinar um mamìfero contra umestado doentio, composição de vacina, uso de umcomposto, e, combinação de componentes paraadministração separada, sequencial ouconcomitante no processo

Country Status (22)

Country Link
US (1) US7074770B1 (pt)
EP (1) EP1107785B1 (pt)
JP (1) JP2002523469A (pt)
KR (1) KR20010072983A (pt)
CN (1) CN1326358A (pt)
AT (1) ATE411043T1 (pt)
AU (1) AU747643B2 (pt)
BR (1) BR9913323A (pt)
CA (1) CA2341544A1 (pt)
CZ (1) CZ2001717A3 (pt)
DE (1) DE69939747D1 (pt)
ES (1) ES2313791T3 (pt)
GB (1) GB9818627D0 (pt)
HU (1) HUP0103214A3 (pt)
IL (1) IL141623A0 (pt)
NO (1) NO20010922L (pt)
NZ (1) NZ510206A (pt)
OA (1) OA11644A (pt)
PL (1) PL346299A1 (pt)
TR (1) TR200101256T2 (pt)
WO (1) WO2000012121A1 (pt)
ZA (1) ZA200101539B (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7223739B1 (en) 1995-06-07 2007-05-29 Powderject Vaccines, Inc. Adjuvanted genetic vaccines
AU3593200A (en) 1999-02-09 2000-08-29 Powderject Vaccines, Inc. (mycobacterium tuberculosis), immunization
GB9923309D0 (en) * 1999-10-01 1999-12-08 Glaxo Group Ltd Assay
EP1227840B1 (en) * 1999-11-03 2007-10-03 Powderject Vaccines, Inc. Adjuvanted genetic vaccines
SI1227840T1 (sl) * 1999-11-03 2008-02-29 Powderject Vaccines Inc Genetske vakcine z adjuvansom
AU2001251491A1 (en) * 2000-04-11 2001-10-23 Galenica Pharmaceuticals, Inc. Lipophilic aromatic aldehyde and ketone derivatives and the use thereof as immunostimulants and adjuvants
GB0023008D0 (en) * 2000-09-20 2000-11-01 Glaxo Group Ltd Improvements in vaccination
CN100567242C (zh) * 2003-06-27 2009-12-09 协和发酵麒麟株式会社 Hsp90家族蛋白质阻断剂
CN100415876C (zh) * 2003-09-05 2008-09-03 杭州浙大康泰生物技术有限公司 艾滋病重组腺病毒疫苗
JP5785559B2 (ja) 2009-12-16 2015-09-30 クロンテック ファーマ アーベー 注射針および注射装置
CN103717249B (zh) 2011-06-15 2017-03-22 克洛恩泰克制药股份公司 注射针和装置
PT2797416T (pt) * 2011-12-28 2017-10-23 Global Blood Therapeutics Inc Compostos de benzaldeído substituído e métodos para a sua utilização no aumento da oxigenação de tecidos
ES2790358T3 (es) 2011-12-28 2020-10-27 Global Blood Therapeutics Inc Compuestos de heteroaril aldehído sustituido y métodos para su uso en el aumento de la oxigenación tisular
WO2014064534A2 (en) 2012-10-05 2014-05-01 Chrontech Pharma Ab Injection needle, device, immunogenic compositions and method of use
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
CN105073728A (zh) 2013-03-15 2015-11-18 全球血液疗法股份有限公司 化合物及其用于调节血红蛋白的用途
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
MY180206A (en) 2013-03-15 2020-11-25 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
AP2015008718A0 (en) 2013-03-15 2015-09-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
DK3102208T3 (da) 2014-02-07 2021-03-08 Global Blood Therapeutics Inc Krystallinsk polymorf af den frie base af 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyd
US10946096B2 (en) 2014-02-26 2021-03-16 The Board Of Regents Of The University Of Texas System Nitrobenzaldehyde proton release for manipulation of cellular acidosis
KR102626155B1 (ko) 2015-03-06 2024-01-17 비욘드스프링 파마수티컬스, 인코포레이티드. Ras 돌연변이와 관련된 암의 치료 방법
US11267807B2 (en) * 2015-10-28 2022-03-08 The Brigham And Women's Hospital, Inc. Use of small molecule inhibitors to KLF10 for modulation of T regulatory cells and cancer immunotherapy
MA43373A (fr) 2015-12-04 2018-10-10 Global Blood Therapeutics Inc Régimes posologiques pour 2-hydroxy-6-((2- (1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)méthoxy)benzaldéhyde
US10912748B2 (en) 2016-02-08 2021-02-09 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
AR108435A1 (es) 2016-05-12 2018-08-22 Global Blood Therapeutics Inc Proceso para sintetizar 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)-piridin-3-il)metoxi)benzaldehído
TWI778983B (zh) 2016-10-12 2022-10-01 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
EP3565812B1 (en) 2017-01-06 2023-12-27 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
WO2019147615A1 (en) 2018-01-24 2019-08-01 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing thrombocytopenia via the administration of plinabulin
CN109232238B (zh) * 2018-08-29 2022-05-17 北京勤邦生物技术有限公司 吉非罗齐半抗原、人工抗原和抗体及其制备方法和用途
WO2020072377A1 (en) 2018-10-01 2020-04-09 Global Blood Therapeutics, Inc. Modulators of hemoglobin for the treatment of sickle cell disease
CN112778155B (zh) * 2019-11-11 2023-08-11 大连万春布林医药有限公司 妥卡雷琐衍生物及其用途
JP2023539352A (ja) * 2020-08-26 2023-09-13 ガートルード・バイオメディカル・ピーティーワイ・リミテッド 抗ウイルスｓｏｘ阻害剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620896A (en) * 1992-03-23 1997-04-15 University Of Massachusetts Medical Center DNA vaccines against rotavirus infections
DE69306545T2 (de) * 1992-10-01 1997-04-03 Wellcome Found Tucaresol als Mittel zur Immunopotentierung
TW360548B (en) * 1993-04-08 1999-06-11 Powderject Res Ltd Products for therapeutic use
WO1995020660A2 (en) 1994-01-27 1995-08-03 University Of Massachusetts Medical Center Immunization by inoculation of dna transcription unit

Also Published As

Publication number Publication date
NZ510206A (en) 2003-08-29
HUP0103214A3 (en) 2003-10-28
CN1326358A (zh) 2001-12-12
KR20010072983A (ko) 2001-07-31
US7074770B1 (en) 2006-07-11
IL141623A0 (en) 2002-03-10
PL346299A1 (en) 2002-01-28
CZ2001717A3 (cs) 2001-10-17
NO20010922D0 (no) 2001-02-23
AU747643B2 (en) 2002-05-16
GB9818627D0 (en) 1998-10-21
AU5740299A (en) 2000-03-21
TR200101256T2 (tr) 2001-10-22
HUP0103214A2 (hu) 2001-12-28
ZA200101539B (en) 2002-02-25
WO2000012121A1 (en) 2000-03-09
ATE411043T1 (de) 2008-10-15
CA2341544A1 (en) 2000-03-09
EP1107785B1 (en) 2008-10-15
NO20010922L (no) 2001-04-23
EP1107785A1 (en) 2001-06-20
DE69939747D1 (de) 2008-11-27
ES2313791T3 (es) 2009-03-01
OA11644A (en) 2004-11-22
JP2002523469A (ja) 2002-07-30

Similar Documents

Publication Publication Date Title
BR9913323A (pt) Processo para vacinar um mamìfero contra umestado doentio, composição de vacina, uso de umcomposto, e, combinação de componentes paraadministração separada, sequencial ouconcomitante no processo
BR0113400A (pt) Método para seleção de peptìdeo
PT815235E (pt) Vacinas para peste
BR0008161A (pt) Uso de uma composição terapêutica para tratamento de uma célula tumoral, composição terapêutica, e kit para tratamento de uma célula tumoral
PT912898E (pt) Metodo imunologico de deteccao de anticorpos dirigidos contra a transglutaminase (ttg) utilizacao de ttg para o diagnostico e controlo de terapia assim como agente farmaceutico oral contendo ttg
BR9916020A (pt) Compostos e métodos para o tratamento e diagnóstico de infecção por chlamydia
AU7814498A (en) Multivalent (in ovo) avian vaccine
BR0108566A (pt) Método para a regulação negativa in vivo de proteìna amilóide em um animal, incluindo um ser humano e para o tratamento e/ou prevenção e/ou melhora da doença de alzheimer ou outras doenças e condições cartacterizadas por depósitos de amilóide, análogo de um polipeptìdeo amiloidogênico,composição imunogênica, fragmento de ácido nucleico, vetor, célula transformada, composição para induzir a produção de anticorpos contra um polipeptìdeo amiloidogênico, linhagem celular estável, métodos para a preparação de uma célula, para a identificação de um polipeptìdeo amiloidogênico modificado, e para preparação de uma composição imunogênica, uso de um polipeptìdeo amiloidogênico ou de uma subsequência do mesmo, e, uso de um análogo de um polipeptìdeo amiloidogênico
UA49814C2 (uk) Композиція, яка містить антиген вірусу папіломи, спосіб лікування цервікального раку, спосіб лікування гострокінцевої кондиломи
BR9605153B1 (pt) vacina de combinação, e, kit de vacinação.
BR0109150A (pt) Método para administração de um anestésico local a um indivìduo em necessidade de um efeito anestésico local, emplastro, composição, e, recipiente
KR920700674A (ko) 특정 t세포 집단에 의한 발명 반응으로부터 야기되는 질병에 대한 예방접종 및 방법
BR0115847A (pt) Compostos especìficos para receptor para adenosina a1, a2a, e a3 e usos dos mesmos
BRPI0707543B8 (pt) composição de polipeptídeo e uso da mesma
ES2181676T3 (es) Diagnosis y tratamiento de enfermedades autoinmunitarias.
BR9106303A (pt) Imonogeno humano composicao,celula de mamifero,peptido,vacina contra sintomas de esclerose multipla,metodo para tratar ou prevenir doenca com sintomas de esclerose multipla e conjunto para diagnosticar esclerose multipla
AR044234A2 (es) Uso de una composicion que comprende oocistos de eimeria vivos
ATE77047T1 (de) Sebosuppressive topische zubereitungen.
ATE103297T1 (de) Peptid, immunogene zusammensetzung und impfstoff oder medizinische zubereitung, eine methode zur immunisierung eines saeugetieres gegen lhrh und methode zur verbesserung von mea.
DE69033745T2 (de) Oberflächenaktive zusammensetzungen und verfahren
ES2146214T3 (es) Vacunas para actinobacillus pleuropneumoniae.
BR0211566A (pt) Aparelho e método para redução de peso eletricamente condutor
BR9106676A (pt) Peptideo,processo para promover a liberacao de niveis de hormonio de crescimento em um animal,composicao farmaceutica para promover a liberacao de niveis de hormonio de crescimento em animais,uso do composto e processo para promover a liberacao e elevacao de niveis de hormonio de crescimento no sangue
SE9402880D0 (sv) New peptide derivatives
ATE205219T1 (de) Ein verbessertes peptid, immunogene zusammensetzung und impfstoff oder medizinische präparate, eine methode zur immunisierung von tieren gegen das hormon lhrh und analoge des lhrh-tendem-repeat-peptid und deren verwendung als impfstoff

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A, 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1962 DE 12/08/2008.